Literature DB >> 16142345

Clinical significance of MHC class II-associated invariant chain expression in human gastric carcinoma.

Yasuhiro Tamori1, Xiaodong Tan, Kazuhiro Nakagawa, Eiji Takai, Junji Akagi, Toshiro Kageshita, Hiroshi Egami, Michio Ogawa.   

Abstract

MHC class II antigens serve as restricted elements for cell presenting antigens to CD4+ helper T cells. CD4+ T cells and CD8+ cytotoxic T cells, which are tumor-infiltrating lymphocytes (TILs), and play a major role in the survey and attack against tumor cells in primary lesions. Invariant chain (Ii) has several functions in MHC class II-restricted antigen presentation. In addition, Ii is found to be closely involved in the regulation of anti-tumor immunity in several tumor types. However, the significance of Ii expression in tumor cells is not fully illustrated. Immunohistochemical staining of Ii expression was performed in 58 cases of human gastric carcinoma specimens. The prognostic analysis of patients with gastric carcinoma was also performed. A total of 67.2% (39/58) gastric carcinomas were found to be Ii-positive, whereas only 20.7% (12/58) showed positive immunoreactivity with anti-MHC class II determinants. Furthermore, Ii expression showed significant correlation with the differentiation of gastric carcinoma (p<0.05). Ii expression also showed an inverse correlation with the frequency of TILs around carcinoma tissues, as well as with the prognosis of gastric carcinoma (p<0.01). Ii expression is closely correlated with anti-tumor immunity in human gastric carcinoma. Therefore, Ii may serve as an independent clinical marker for poor biological behavior and prognostic analysis in patients with gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16142345

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

1.  Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cells.

Authors:  Azizul Haque; Laela M Hajiaghamohseni; Ping Li; Katherine Toomy; Janice S Blum
Journal:  Cell Immunol       Date:  2007-12-11       Impact factor: 4.868

2.  Endoproteolytic processing of C-terminally truncated NF-kappaB2 precursors at kappaB-containing promoters.

Authors:  Guoliang Qing; Zhaoxia Qu; Gutian Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-15       Impact factor: 11.205

3.  The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.

Authors:  James A Thompson; Minu K Srivastava; Jacobus J Bosch; Virginia K Clements; Bruce R Ksander; Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Immunother       Date:  2007-08-28       Impact factor: 6.968

Review 4.  HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.

Authors:  M Campoli; S Ferrone
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

5.  CD74 interferes with the expression of fas receptor on the surface of lymphoma cells.

Authors:  Zuzana Berkova; Shu Wang; Xue Ao; Jillian F Wise; Frank K Braun; Abdol H Rezaeian; Lalit Sehgal; David M Goldenberg; Felipe Samaniego
Journal:  J Exp Clin Cancer Res       Date:  2014-10-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.